NewAmsterdam Accounts Payable from 2010 to 2024
NAMS Stock | 20.84 0.21 1.00% |
Accounts Payable | First Reported 2010-12-31 | Previous Quarter 16.9 M | Current Value 10 M | Quarterly Volatility 5.4 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 28.4 K, Net Interest Income of 3.6 M or Interest Income of 11.8 M, as well as many indicators such as Price To Sales Ratio of 68.31, Dividend Yield of 0.0 or PTB Ratio of 3.02. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Accounts Payable |
Latest NewAmsterdam Pharma's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of NewAmsterdam Pharma over the last few years. An accounting item on the balance sheet that represents NewAmsterdam Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of NewAmsterdam Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. NewAmsterdam Pharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
Accounts Payable | 10 Years Trend |
|
Accounts Payable |
Timeline |
NewAmsterdam Accounts Payable Regression Statistics
Arithmetic Mean | 3,410,576 | |
Geometric Mean | 1,115,605 | |
Coefficient Of Variation | 157.56 | |
Mean Deviation | 4,287,823 | |
Median | 487,060 | |
Standard Deviation | 5,373,642 | |
Sample Variance | 28.9T | |
Range | 16.4M | |
R-Value | 0.74 | |
Mean Square Error | 14.2T | |
R-Squared | 0.54 | |
Significance | 0 | |
Slope | 886,209 | |
Total Sum of Squares | 404.3T |
NewAmsterdam Accounts Payable History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last Reported | Projected for Next Year | ||
Accounts Payable | 16.9 M | 10 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.